Abstract: Primary immunodeficiencies (PID) are congenital disorders of immune competence, which are mainly characterized by a pathological susceptibility to infection. More than 240 PID disease entities have been defined so far, accounting for a broad spectrum of clinical symptoms and severity. Severe PID are increasingly becoming appreciated as a relevant health problem, and diagnostic procedures and screening profiles to allow earliest possible diagnosis on a population scale have already been developed in the USA and few European countries. The most severe PID are characterized by significant mortality in the first years of life, as well as serious morbidity with irreversible organ damage. This applies in particular to PID that are defined by the absence or functional anergy of T-lymphocytes (severe combined immunodeficiency; SCID) or B-lymphocytes (e.g., X-linked agammaglobulinemia; XLA). A strategy to improve the outcome of severe PID by prompt diagnosis and immediate adequate treatment is screening newborns for the presence of T and B cells. 
Introduction
Mass screening of newborn infants started in the early 1960s in the EU with a method for detecting phenylketonuria. Once this procedure was established, other disorders were considered for newborn screening (NBS), prompting the creation of guidelines to help in deciding which diseases were suitable for population-based screening. Different concepts for NBS evaluation exist, yet most EU countries require compliance of the proposed diseases with the expanded Wilson-Jungner framework [1] [2] [3] .
Primary immunodeficiency diseases (PID) represent a heterogeneous group of inborn defects of the immune system that result in recurrent and severe infectious complications. Most PID can be characterized by a functional impairment of the tightly regulated capacity of leukocytes to clear infections, yet some disorders are due to limited differentiation of cells of the lymphoid lineage or increased lymphocyte apoptosis. Newborns that cannot produce T cells themselves are characterized by a severe T-cell lymphopenia, associated in many cases with the clinical diagnosis of "severe combined immunodeficiencies" (SCID).
Newborns with SCID appear healthy at birth and remain clinically "silent" during the first months of life until maternal antibodies which confer a certain degree of protection against infection vanish and the inability to develop T cells cannot be compensated anymore by maternal immunity. SCID is lethal during the first two years of life, mandating curative haematopoietic stem cell transplantation (HSCT) or gene therapy. In addition, for adenosine deaminase (ADA) SCID, enzyme replacement therapy (ERT) also offers a treatment alternative. These therapies work best if initiated before overwhelming infectious complications occur.
The clinical severity and the associated economic burden of a delayed diagnosis, as well as the potentially fatal outcome if not treated promptly, emphasize the importance of early identification of the affected newborns. Although the condition is rare, precise estimates of its frequency based on large population studies are lacking. Early data from pilot screening programs in the USA suggest that one in 30,000-50,000 infants may be born with SCID. Although incidence rates are not strictly part of the extended Wilson-Jungner evaluation framework, SCID may well be detected at frequencies similar to disorders of fatty acid or amino acid metabolism that are screened for in numerous EU country NBS programs.
The benefit of a neonatal screening for SCID is best exemplified by the extremely effective treatment for SCID, with approximately 95% survival following HSCT when transplantation is performed before 3.5 months of age. However, if SCID is not screened for at birth, patients will suffer from recurrent infections and survival is severely compromised. Furthermore, following onset of infectious periods, the pharmacological preparation for stem cell transplantation has to be adjusted and becomes more difficult, often resulting in less successful engraftment. Thus, early intervention not only reduces the disease-related mortality and morbidity but is also curative, in contrast to the dietary therapeutic approaches that have to be taken in the metabolic diseases currently screened for.
Severe Combined Immunodeficiency and Severe T-Cell Lymphopenia-A Life-Threatening Group of Disorders
Severe combined immunodeficiency (SCID) is a group of life-threatening immune disorders arising from a variety of genetic defects that lead to the absence of lymphocyte development and function. Nearly all patients with SCID have absent T-cells, and are further grouped by absence or presence of B-cells and NK-cells (Figure 1 ). The diagnosis of SCID is a pediatric emergency, as affected children have extreme susceptibility to bacterial, viral, fungal, and opportunistic infections, which are fatal in the first 1-2 years of life without curative treatment [4, 5] . In most cases, children with SCID appear well at birth and present with recurrent severe infections and failure to thrive at 3-6 months as passively transferred protective maternal immunoglobulins are diminishing [6] [7] [8] . Severe T-cell deficiency syndromes may also present early in infancy with autoimmune-like phenomena and susceptibility to infection. These disorders may be caused by hypomorphic mutations in known SCID-causing genes. available for ADA-SCID and X-SCID) can be undertaken. Early diagnosis allows timely start of preventive measures, including prophylactic antibiotics, antifungal or antiviral treatment and immunoglobulin replacement therapy, as well as avoidance of live vaccines. In addition, early searches for HLA-matched haematopoietic stem cell (HSC) donors are enabled [9] . This is important, as HSCT in the first 3.5 months of life is associated with up to 95% chance of survival, irrespective of donor type or type of SCID [10] [11] [12] , compared with 76% survival for later HSCT [13] .
Newborn Screening for SCID and Severe T-Cell Lymphopenia: TREC Assay
There has been a long-standing search for a suitable biomarker for normal T-cell development and for methods that allow NBS for SCID. Newborn screening for SCID was initially proposed in the 1990s by Puck and Buckley, suggesting that a complete (differential) blood count might help diagnose the disease based on a reduced absolute lymphocyte count in blood. As this method relied on fresh blood samples, the efforts for sample logistics and handling prevented its large-scale implementation. test results. ELISA-like immunoassays for Interleukin-7 have also been proposed for SCID screening, yet technical issues of inferior sample stability and tedious protein purification have prevented their broader application [14] . Similarly, bead-capture assays for the T-cell receptor-CD3 complex and CD45 have been developed, but false negative results in SCID patients with maternal engraftment or expansion of oligoclonal T cells was encountered, thereby disqualifying this technique from implementation [15] . Normal T-cell development requires production of precursor T-cells in the bone marrow and subsequent processing of T-cells in the thymus. Although SCID can arise from a variety of genetic defects, there is an abnormality of T-cell development in the thymus in all cases. During normal thymic processing, T cells undergo receptor gene splicing and rearrangement, leading to intracellular accumulation of DNA by-products known as T-cell receptor excision circles (TRECs) [16, 17] . When used in NBS assays, TRECs are a surrogate marker of newborns' capability to produce T cells, which is severely hampered in SCID patients. Suitable TREC assays are based on DNA extracted from a regular dried blood spot collected at birth and can be determined either by quantitative or end-point PCR ( Figure 2 ). Before formation of TRECs in T cell precursors (A), the primer and probe design will not lead to detectable amplification, as the signal joint is only found when circular end-joining is completed (B). The ~100 bp sjTREC amplicon is amplified using sequence-specific oligonucleotide primer and hydrolysis probes in a typical real-time qPCR reaction.
TRECs do not replicate in dividing cells and are diluted out upon cellular division. They are therefore only found in recent thymic emigrant naive T-cells [8, 9] (Figure 3A ). This aspect is important, as in certain conditions such as engraftment of maternal T-cells or expansion of a few oligoclonal T-cells in Omenn syndrome, a substantial amount of T-cells can be found in an infant with SCID. As these T-cells have undergone multiple rounds of cell division, TRECs are diluted and the TREC value is low despite high numbers of T-cells in peripheral blood [6] .
(A) (B) Figure 3 . (A) Normal distribution TREC copies from dried blood spot analysis in n = 1200 healthy newborns, as well as 10 samples with patients with low TREC copy numbers during initial screening; (B) Normal distribution kappa-deleting recombination excision circles (KREC) copies from dried blood spot analysis in n = 1200 healthy newborns, as well as 10 samples with patients with low KREC copy numbers during initial screening.
As some leaky, variant, or delayed-onset forms of SCID might not be detected at birth based on the TREC assay, the addition of other screening markers such as KREC [18] , which detect defects of B-cell development has been proposed [19] [20] [21] (Figure 3B ).
TREC Assay Based Newborn Screening Programs
Population-based screening is the only means to detect SCID before the onset of life-threatening infections in most patients, as more than 80% lack a positive family history [22, 23] . In addition, SCID is the first condition being screened for in population-wide newborn screening that can actually be cured. Newborn screening for SCID by the TREC assay in the USA began in 2008 in Wisconsin and has now been extended to 23 states, the District of Columbia and the Navajo Nation [24] . Available data on >3 million newborns from the first 5 years of screening in 11 programs in the USA reported an incidence of 1 in 58,000 live births (95% CI, 1/46,000-1/80,000) with an overall survival of 87%. The majority of cases had typical SCID (42/52 identified SCID cases), 10/52 infants had leaky SCID and 1/52 had Omenn syndrome. No cases of SCID were missed by initial TREC screening but detected later. Survival of identified infants with SCID who received HSCT, GT or enzyme replacement was 92%. Specificity was high at >99.8%, and in addition to 52 cases of typical SCID, leaky SCID and Omenn syndrome, other cases of non-SCID severe T-cell lymphopenia were detected. Identification of non-SCID severe T-cell lymphopenia allows to avoid life vaccines and to install appropriate infection prophylaxis and follow-up [25] [26] [27] . Non-SCID diseases with severe T-cell deficiency detected by TREC screening can be grouped in (1) congenital syndromes with T-cell impairment; (2) secondary T-cell impairment; (3) preterm birth; (4) variant SCID; (5) unspecified T-cell lymphopenia. In the above report from the USA the incidence of non-SCID T-cell lymphopenia was 1:14,000 using a definition of <1500 T-cells/μL as cut-off and excluding preterm infants [24] . 33% of the infants with non-SCID T-cell lymphopenia had congenital syndromes known to be associated with T-cell lymphopenia: 57% had DiGeorge syndrome/chromosome 22q11.2 deletion, 15% had trisomy 21, 3% each had ataxia telangiectasia or trisomy 18, and 2% had CHARGE syndrome. Non-SCID T-cell lymphopenia was attributed to other medical conditions in 28%, of which 26% had congenital heart disease, followed by multiple other congenital anomalies, loss into third space due to vascular leakage, or gastrointestinal anomalies.
Population-based newborn screening by TRECs has thus provided a new incidence of SCID, higher than the incidence of 1:100,000 estimated from retrospective clinical diagnoses, suggesting that SCID has previously been underdiagnosed in infants with fatal infections. SCID newborn screening has been recommended by the US Department of Health and Human Services Secretary across all states [28] , and many other countries worldwide are beginning to include TRECs screening in their screening programs, or are in the phase of pilot-studies or applications of respective proposals to their medical authorities. Other states or provinces currently using the TREC assay for prospective population-wide newborn screening are: Ontario/Canada, Taiwan and Sao Paulo/Brazil.
Newborn screening for PID (TREC-only) is an established test within the state wide screening programs in the most populous states in the USA and in Taiwan. Europe is currently lagging behind but pilot screening programs have recently been initiated in Sweden [19] , Germany [20] , UK [29] , France [30] , and Spain [31] and the rationale for newborn screening (originally established by Wilson and Jungner [1] ) has recently been outlined for patients with PID [4, 9] . Proposals to include SCID diagnostics in population-based newborn screening programs have been submitted to national agencies in Germany, the Netherlands, the UK, and Switzerland.
TREC Screening Algorithm
Screening for severe T-cell lymphopenia by TREC in the USA is not standardized and employs different methods, leading to marked differences in cut-offs for the number of newly formed T-cells in the ongoing screening programs in the various states. This, in turn, has resulted in marked differences in the number of patient recalls and diagnostic procedures (fluorescence activated cell sorting, (FACS)), with an almost ten-fold difference between states [24] .
To ensure adequate follow-up of infants with likely SCID identified by TREC screening and to limiting the number of false-positive results at the same time, algorithms have been designed by screening centers together with clinical immunologists. In most cases this will include the following (Figure 4 ). All infants undergo screening by the TREC assay. If normal, no further intervention is recommended. In infants with TREC levels below the cut-off, the first screening card will be retested for TREC as well as DNA amplification by quantifying β-actin or RNase P levels by qRT-PCR. If the β-actin level is normal and TRECs are still below the cut-off the primary care provider is contacted for two scenarios (1) an emergency scenario-if TRECs are undetectable (~1 in 20,000 cases, [24] ), the infant needs urgent confirmatory testing by flow cytometry and treatment by a clinical immunologist (2) an intermediate scenario-if TRECs are detectable, yet below the established local cut-off value, re-testing of a second screening card is performed (tracking process): Tracking of newborns is thus initiated in case of repeated abnormal test results for TREC and/or KREC copy numbers after examination of at least three independent dried blood punches of the first dried blood spot submitted.
As first action within the tracking procedure, the obstetric unit ("doctor-doctor" contact) and the parents of the newborn ("doctor-patient" contact) should be contacted to obtain additional information on the status of the child (stage 1). Since repeated abnormal TREC and/or KREC test results can occur especially in preterm infants (<32nd week of pregnancy), children with syndromic diseases (e.g., trisomy 21 or 22q11 microdeletion), metabolic diseases (such as propionyl-CoA carboxylase deficiency or methylmalonic aciduria), and severe congenital infections or malformations with subsequent lymphocyte extravasation (e.g., neonatal sepsis or gastroschisis), it is important to gather and compile additional examination findings to evaluate a suspected diagnosis of a severe congenital immunodeficiency.
While the parents of the newborn should be informed without delay after the examination of the second separate dried blood card, even if the findings are normal, a detailed explanation of the significance of the test results, if they are abnormal again, will be provided only at a specialized immunodeficiency center. The parents will be directed to such a center in the area (stage 2), and the center will be informed about the patient to be expected.
Subsequently, a specialized treatment center should be selected that is close to home: in the case of suspected severe T-and/or B-lymphopenia, intensive hygiene measures and possibly early, strict isolation to prevent opportunistic infections are necessary steps to be taken. In order to perform HSCT or gene therapy, a transfer to a specialized transplant center may be necessary. Only such centers should be selected that have already gained experience in this field in patients with primary immunodeficiencies (optimized conditioning and transplantation protocols).
Fiscal Implications of SCID Newborn Screening
A number of USA states have already adopted SCID NBS, based on the TREC assay. The success of these programs so far has led to a nationwide recommendation of NBS for SCID by the USA Department of Health and Human Services [24] . The cost-effectiveness analysis of case finding SCID screening has been shown to be economically favorable in relation to the expenditures on medical healthcare for this group of disorders. As one of the most important determining factors, detection of SCID at birth allows for curative treatment before the occurrence of complications that often require prolonged and expensive intensive care management that markedly increases healthcare costs. The rapid access to curative therapy also reduces the social burden, tremendous impairment in quality-of-life and the inestimable social costs associated with an undiagnosed SCID. Thus far, only five cost analyses of the SCID newborn screening programs have been published based on data from the USA [23, [32] [33] [34] and the UK [35] . They all conclude that in addition to saving lives, newborn screening for SCID results in a reduction in overall health-care costs.
Outlook on Expansion of NBS to Detect More Immune Deficiencies
Developing the concept of cost-efficacy in newborn screening further, it has been proposed to multiplex the TREC screening assay with other biomarkers that would allow identification of diseases suitable to be included in population-scale screening programs. Severe inborn immunodeficiency diseases characterized by the absence of B-cells, resembling the clinical diagnosis of primary agammaglobulinemias, can be detected at birth when quantifying KRECs in a multiplex qPCR or endpoint PCR reaction together with TRECs. As both biomarkers can be assessed within the same dried blood spot sample, most infrastructural and technical resources can be used without additional efforts or expenses when the multiplex assay is performed. The additional technical cost fraction of an add-on KREC assessment is less than 6% of the total assay costs. However, analysis of KREC copy numbers in dried blood spot specimen, as a tool for newborn screening, requires further validation to ensure sufficient sensitivity and specificity before broad implementation can be expected.
